Regenics is a Norwegian marine biotech company developing salmon roe based products for the international wound healing and skin care markets. The company was founded by Professor Philippe Collas, Professor at the University of Oslo, Jan Remmereit, founder of series of companies, a.o. Natural ASA and Tore H. Rasmussen, present chairman of the Board. 

The company was based on utilizing the intense biological growth and reprogramming activity of the marine egg cell on already differentiated cells, a discovery first demonstrated in the late eighties for nuclear transfer and later for cytoplasmic extracts. In essence cytoplasmic extract from the salmon egg have to abillity to reprogram already differentited cells. Regenics has focussed on human skin cells and develops products for wound healing, particularly hard to heal wounds and wounds that have partial necrosis or cell damage in the dermis area of the skin. As a byfinding of the research of the effects of salmon eggs, Regenics has commericalized salmon roe based extracts to the cosmetic industry both in Norway, US and Asia.

The company have succeded in obtaining EU as well as Norwegian based R&D grants and funds for R&D, Development  and commercial support.

For more on the salmon roe concept, click on the tab "The Concept" 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.